NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 61)
Posted On: 09/20/2024 5:07:14 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of semaglutide, the GLP-1 drug used in the study, and tolerability. The study also measured blood glucose and insulin levels, ultimately serving as an indicator in the potential treatment of diabetes and weight loss. GLP-1 drugs have been lauded for their potential to treat diabetes,” a recent article reads. “Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patents and to industry,” Lexaria’s CEO Chris Bunka was quoted as saying.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of semaglutide, the GLP-1 drug used in the study, and tolerability. The study also measured blood glucose and insulin levels, ultimately serving as an indicator in the potential treatment of diabetes and weight loss. GLP-1 drugs have been lauded for their potential to treat diabetes,” a recent article reads. “Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patents and to industry,” Lexaria’s CEO Chris Bunka was quoted as saying.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼